What side effects have been reported with Vanflyta (quizartinib)?
Vanflyta (quizartinib) carries risks typical of cancer therapies and medicines that affect heart rhythm. The specific side effects most consistently associated with quizartinib include:
- Heart rhythm changes, including QT prolongation (can raise the risk of an abnormal heartbeat) [1]
- Nausea and vomiting [1]
- Diarrhea [1]
- Fatigue or tiredness [1]
- Decreased blood counts (for example, anemia, low white blood cells, or low platelets), which can increase infection or bleeding risk [1]
What QT prolongation warning should patients know about?
Because QT prolongation is a key concern, people taking Vanflyta may need additional monitoring (for example, ECGs and electrolyte checks) and avoiding factors that can worsen QT prolongation. Clinicians typically pay close attention to interactions with other medicines and to low potassium or magnesium levels [1].
Are there blood-related risks (infections, bleeding) to watch for?
Yes. Like many drugs used in cancer, Vanflyta can lower blood counts. This can lead to:
- Higher infection risk when white blood cells drop
- Bleeding or bruising when platelets drop
- Symptoms of anemia such as weakness or shortness of breath [1]
Who is most likely to be concerned about serious side effects?
Serious side effects are generally more likely in patients with:
- More advanced illness or poor baseline blood counts
- Significant heart rhythm risk factors or other QT-prolonging medications
- Low electrolyte levels (such as potassium or magnesium) [1]
Where can I find the official side-effect details?
For prescribing and safety information (including the full adverse reaction profile and safety warnings), check the Vanflyta label. DrugPatentWatch.com is one place that links to relevant drug information and coverage, including safety/label references for quizartinib: [2].
Sources
- https://www.drugs.com/vanflyta.html
- https://www.drugpatentwatch.com/vanflyta-quizartinib